KPKiran Pandey

Kiran Pandey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kiran Pandey has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A prodrug targeting CIM6P/IGF2R enhances memory in healthy mice and reverses deficits in an Angelman syndrome mouse model

    by Francesca Aria, Christopher J. Arp, Emmanuel Prikas, Sebastian Goodwin-Groen, Kiran Pandey, Leonardo Munari, Shlok Patel, Dirk Trauner, Cristina M. Alberini

    Devastating diseases of the central nervous system (CNS), such as neurodevelopmental disorders and neurodegenerative diseases, carry severe neurological symptoms, including cognitive impairment –a decline characterized by learning and memory problems. Currently, no efficacious treatment is available for preventing or treating these diseases; therefore, there is a great unmet need to find novel, effective therapeutics. Previous studies have shown that insulin-like growth factor 2 (IGF2) and mannose 6-phosphate (M6P), two major ligands of the cation-independent M6P/IGF2 receptor (CIM6P/IGF2R), significantly enhance memory and prevent forgetting in healthy animals. Furthermore, they reverse most core symptoms in mouse models of neurodevelopmental disorders, such as Angelman syndrome (AS mice) and autism spectrum disorder, and of neurodegenerative diseases. Starting from the M6P chemical structure, we designed the novel prodrug PMP1. We tested its effects on learning and memory in healthy mice as well as on behavioral deficits in AS mice. We report that both subcutaneous and oral administrations of PMP1 significantly enhance memory strength and persistence in healthy mice. Furthermore, they reverse memory impairments and motor deficits in AS mice. The effect of PMP1 requires the expression of CIM6P/IGF2R in the hippocampus, and the treatment does not elicit any detectable adverse effects. The highest effects were achieved with the same PMP1 maximum effective dose via either route of administration; however, oral administration produced a more prolonged effect. Thus, the novel small-molecule prodrug PMP1, through CIM6P/IGF2R, is a promising therapeutic candidate for Angelman syndrome and an effective memory enhancer.


  • Open Access

    Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions

    by Waleska Kerllen Martins, Maryana Do Nascimento da Silva, Kiran Pandey, Ikuko Maejima, Ercília Ramalho, Vania Claudia Olivon, Susana Nogueira Diniz, Daniel Grasso


  • Autophagy coupled to translation is required for long-term memory

    by Kiran Pandey, Xiao-Wen Yu, Adam Steinmetz, Cristina M. Alberini

    An increase in protein synthesis following learning is a fundamental and evolutionarily conserved mechanism of long-term memory. To maintain homeostasis, this protein synthesis must be counterbalanced by mechanisms such as protein degradation. Recent studies reported that macroautophagy/autophagy, a major protein degradation mechanism, is required for long-term memory formation. However, how learning regulates autophagy and recruits it into long-term memory formation remains to be established. Here, we show that inhibitory avoidance in rats significantly increases the levels of autophagy and lysosomal degradation proteins, including BECN1/beclin 1, LC3-II, SQSTM1/p62 and LAMP1, as well as autophagic flux in the hippocampus. Moreover, pharmacological inhibition or targeted molecular disruption of the learning-induced autophagy impairs long-term memory, leaving short-term memory intact. The increase in autophagy proteins results from active translation of their mRNA and not from changes in their total mRNA levels. Additionally, the induction of autophagy requires the immediate early gene Arc/Arg3.1. Finally, in contrast to classical regulation of autophagy in other systems, we found that the increase in autophagy upon learning is dispensable for the increase in protein synthesis. We conclude that coupling between learning-induced translation and autophagy, rather than translation per se, is an essential mechanism of long-term memory. Abbreviations: AAV: adeno-associated virus; ARC/ARG3.1: activity regulated cytoskeletal-associated protein; ATG: autophagy related; DG: dentate gyrus; GFP: green fluorescent protein; IA: inhibitory avoidance; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; ODN: oligodeoxynucleotide; qPCR: quantitative polymerase chain reaction; SBI: SBI0206965; SQSTM1/p62: sequestosome 1; SUnSET: surface sensing of translation; TRAP: translating ribosome affinity purification; ULK1: unc-51 like kinase 1


  • Open Access

    A role for CIM6P/IGF2 receptor in memory consolidation and enhancement

    by Xiao-Wen Yu, Kiran Pandey, Aaron C Katzman, Cristina M Alberini

    Cation-independent mannose-6-phosphate receptor, also called insulin-like growth factor two receptor (CIM6P/IGF2R), plays important roles in growth and development, but is also extensively expressed in the mature nervous system, particularly in the hippocampus, where its functions are largely unknown. One of its major ligands, IGF2, is critical for long-term memory formation and strengthening. Using CIM6P/IGF2R inhibition in rats and neuron-specific knockdown in mice, here we show that hippocampal CIM6P/IGF2R is necessary for hippocampus-dependent memory consolidation, but dispensable for learning, memory retrieval, and reconsolidation. CIM6P/IGF2R controls the training-induced upregulation of de novo protein synthesis, including increase of Arc, Egr1, and c-Fos proteins, without affecting their mRNA induction. Hippocampal or systemic administration of mannose-6-phosphate, like IGF2, significantly enhances memory retention and persistence in a CIM6P/IGF2R-dependent manner. Thus, hippocampal CIM6P/IGF2R plays a critical role in memory consolidation by controlling the rate of training-regulated protein metabolism and is also a target mechanism for memory enhancement.


  • Open Access

    Histone deacetylase inhibition facilitates massed pattern-induced synaptic plasticity and memory

    by Kiran Pandey, Kaushik P. Sharma, Shiv K. Sharma

    Massed training is less effective for long-term memory formation than the spaced training. The role of acetylation in synaptic plasticity and memory is now well established. However, the role of this important protein modification in synaptic plasticity induced by massed pattern of stimulation or memory induced by massed training is not well understood. Here we show that increasing the level of acetylation enhances long-term potentiation induced by massed pattern of high frequency stimulation. Furthermore, enhancing acetylation level facilitates long-term memory by massed training. Thus, increasing acetylation level facilitates synaptic plasticity and memory by massed patterns.


  • Open Access

    Activity-Dependent Acetylation of Alpha Tubulin in the Hippocampus

    by Kiran Pandey, Shiv Kumar Sharma

    Posttranslational modifications in proteins play critical roles in synaptic plasticity and memory. In addition, the enduring form of long-term potentiation (LTP) and long-term memory require synthesis of proteins. Some of the mRNAs are present in the dendrites and are locally translated into proteins. Microtubules play critical roles in neuronal transport including the transport of mRNAs from the cell body to the dendrites. Here, we show that KCl depolarization increases acetylation of α-tubulin, a constituent of microtubules, in the CA1 region of the hippocampal slices. Furthermore, activation of N-methyl-d-aspartate receptor, a type of glutamate receptor that plays critical roles in LTP and memory, also enhances α-tubulin acetylation. These results show that acetylation of α-tubulin is modulated in an activity-dependent manner.


  • Regression of Dalton’s lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand

    by Raj K. Koiri, Surendra K. Trigun, Lallan Mishra, Kiran Pandey, Deobrat Dixit, Santosh K. Dubey

    A novel ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide (Ru(II)-CNEB) was found to interact with and inhibit M4-lactate dehydrogenase (M4-LDH), a tumor growth supportive enzyme, at the tissue level. The present article describes modulation of M4-LDH by this compound in a T-cell lymphoma (Dalton’s Lymphoma: DL) vis a vis regression of the tumor in vivo. The compound showed a dose dependent cytotoxicity to DL cells in vitro. When a non toxic dose (10 mg/kg bw i.p.) of Ru(II)-CNEB was administered to DL bearing mice, it also produced a significant decline in DL cell viability in vivo. The DL cells from Ru(II)-CNEB treated DL mice showed a significant decline in the level of M4-LDH with a concomitant release of this protein in the cell free ascitic fluid. A significant increase of nuclear DNA fragmentation in DL cells from Ru(II)-CNEB treated DL mice also coincided with the release of mitochondrial cytochrome c in those DL cells. Importantly, neither blood based biochemical markers of liver damage nor the normal patterns of LDH isozymes in other tissues were affected due to the treatment of DL mice with the compound. These results were also comparable with the effects of cisplatin (an anticancer drug) observed simultaneously on DL mice. The findings suggest that Ru(II)-CNEB is able to regress Dalton’s lymphoma in vivo via declining M4-LDH and inducing mitochondrial dysfunction–apoptosis pathway without producing any toxicity to the normal tissues.